Nektar Therapeutics (NKTR)

Executive Summary

Nektar Therapeutics is a clinical-stage biotechnology company advancing novel IL-2 pathway agonists to treat autoimmune and inflammatory diseases by selectively expanding regulatory T cells. The company has pivoted from oncology to focus on rezpegaldesleukin (REZPEG), its lead candidate in Phase 2b trials for alopecia areata and atopic dermatitis. Nektar recently completed enrollment in a Phase 2b alopecia areata study (NCT06340360) with top-line data expected in mid-2026, and a separate Phase 2b atopic dermatitis trial is also ongoing. Despite prior setbacks in oncology, Nektar maintains a strong balance sheet with ~$300M in cash and a proven track record of partnerships (e.g., with Bristol Myers Squibb and Pfizer). Successful Phase 2b readouts could validate the immunoregulatory platform and unlock significant value, but execution risk remains high given historical program terminations. The company trades at a depressed valuation reflecting skepticism, offering asymmetric upside if REZPEG demonstrates efficacy.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b top-line data for rezpegaldesleukin in alopecia areata60% success
• H2 2026Phase 2b top-line data for rezpegaldesleukin in atopic dermatitis50% success
• TBDPotential partnership or licensing deal for rezpegaldesleukin30% success